recruitment rate

Clinical safety and efficacy of CT ASPHINA 509 IOLs after implantation

Inclusion Criteria:

Patient informed of the consequences and constraints of the protocol and who has given his/her written informed consent;

• Patients of any gender
• Assured follow-up examinations
• Biometry measurement preferably compatible with the IOLMaster evaluation;
• IOL implanted into the capsular bag with IOL model CT ASPHINA 409MP (UVE material) in one eye with at least 12 months follow up at the time of the postop visit
• Patients who had uncomplicated (no peroperative complication) agedrelated cataract surgery in a healthy eye (beside clinically significant cataract)

Exclusion Criteria:

• • BCVA not available preoperatively or better than 0.3 logMAR pre-op

  • Patients unable to meet the limitations of the protocol or likely of noncooperation during the trial
  • Patients whose freedom is impaired by administrative or legal order
  • Concurrent participation in another drug or device investigation